The first gene therapy injected into the brain against a rare form of epilepsy: the patient is an 8-month-old baby

An eight-month-old boy has become the world's first human to receive a groundbreaking experimental gene therapy directly injected into his brain, marking a major step forward in treating a rare form of epilepsy. The procedure was carried out at the Schneider Children’s Medical Center in Israel and aimed to address a severe genetic condition known as WOREE syndrome, which had left the child with relentless seizures resistant to all conventional treatments. According to reports, one month after the treatment, the boy showed no further episodes of seizures and was discharged from the hospital. The findings were published in the journal Neurobiology of Disease. The child began experiencing continuous and severe seizures just six weeks after birth, despite attempts to manage them with medication. Genetic testing confirmed he had WOREE syndrome, a rare neurological disorder linked to mutations in the WWOX gene. This gene plays a critical role in maintaining the stability of neural networks within the brain. When defective or absent, it leads to catastrophic electrical disruptions, resulting in early-onset epilepsy, profound developmental delays, and a high risk of premature death. Until this treatment, doctors could only attempt to alleviate symptoms, offering no cure. The breakthrough comes from years of research led by Dr. Rami Aqeilan at the Hebrew University of Jerusalem. His team first replicated the disease in mice and demonstrated that introducing a healthy version of the WWOX gene eliminated the symptoms. This success paved the way for the first human trial. Scientists used a modified, harmless virus called AAV9, engineered in the laboratory to carry a functional copy of the WWOX gene. This viral vector has the unique ability to navigate through nerve cells and deliver its genetic cargo directly to the nuclei of neurons. Given the severity of the condition, medical professionals activated a compassionate-use protocol, seeking approval to administer the experimental therapy due to the lack of viable alternatives. The treatment was delivered via a highly precise neurosurgical procedure, injecting the gene therapy directly into the child’s brain. Remarkably, the intervention worked immediately. During the first month of observation, the boy did not experience any of the previously devastating seizures that threatened his survival. However, caution remains necessary, as this is the first case of its kind globally. Long-term outcomes remain uncertain, and the child will require ongoing monitoring over several years to assess whether the introduced gene continues to function properly and whether lost developmental progress can be regained. Beyond the individual story of this patient, the event represents a turning point in global pediatric neurology. Mutations in the WWOX gene are uncommon, though more prevalent among Yemenite Jewish communities, yet they occur worldwide. The technique employed opens the door to potential treatments for numerous other currently untreatable genetic disorders affecting brain development. This advancement underscores a shift in medicine toward personalized therapies tailored to correct specific genetic errors rather than applying a uniform approach. For the first time, scientists have successfully accessed one of the most protected and complex parts of the human body, the brain of an infant, to implement such a correction. The implications extend far beyond this singular case, signaling a new era in addressing genetic diseases that once seemed insurmountable.